• Zijian Wu, Liang Li, Guiling Wu, Youqiong Xie, Jia Li, and Rui Peng.
• College of Acupuncture and Orthopedics.
• Medicine (Baltimore). 2021 Feb 12; 100 (6): e24445e24445.

BackgroundCorrection of calcium (Ca), phosphorus (P), and parathyroid hormone (PTH) disorders is the standard of treatment in non-dialysis patients with chronic kidney disease-mineral and bone disorder (CKD-MBD), but the side effects and adverse reactions brought by western medicine (WM) are still the main problems. More importantly, the lack of protection of kidney function in the treatment greatly affects the health of patients. Although traditional Chinese medicine (TCM), specifically tonifying kidney and strengthen bone (TKSB) therapy is wildly applied for patients with CKD-MBD in China, the evidence of TKSB therapy in the treatment of CKD-MBD is limited. Thus, we pretent to conduct this protocol to evaluate the efficacy and safety of TKSB therapy combined with WM for non-dialysis patients with CKD-MBD.MethodsA system research of randomized controlled trials (RCTs) of TKSB therapy for CKD-MBD will be conducted by 2 investigators from 7 electronic databases. Methodological quality evaluations will be performed by using the Cochrane collaboration tool and data analysis will be conducted by RevMan V5.3 software and STATA v15.0.ResultsThe results of this paper will be submitted to a peer-reviewed journal for publication.ConclusionThis research will determine the safety and efficacy of TKSB therapy in treating non-dialysis patients with CKD-MBD.Inplasy Registration NumberINPLASY2020120086.Copyright © 2021 the Author(s). Published by Wolters Kluwer Health, Inc.

32 keywords...

hide…